Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season-Reference-Cited by-同舟云学术

Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season

Published:2024-01-11 Issue:2 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Smolarchuk Christa¹²^ORCID,Ickert Carla¹²,Zelyas Nathan³,Kwong Jeffrey C⁴⁵⁶⁷⁸,Buchan Sarah A⁸⁶⁴⁹¹⁰

Affiliation:

1. These authors contributed equally to this work and share first authorship

2. Public Health Analytics, Alberta Health, Edmonton, Alberta

3. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada

4. Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

5. University Health Network, Toronto, Canada

6. Public Health Ontario, Toronto, Canada

7. Department of Family and Community Medicine, University of Toronto, Toronto, Canada

8. ICES, Toronto, Canada

9. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

10. Centre for Vaccine Preventable Diseases, University of Toronto, ON, Canada

Abstract

Timely and precise influenza vaccine effectiveness (VE) estimates are needed to guide public health messaging and impact vaccine uptake immediately. Using routinely collected laboratory, vaccination and health administrative data from Alberta, Canada, we estimated influenza VE against infection for the 2023/24 season on a near real-time basis, to late December, at 61% (95% CI: 58–64) against influenza A(H1N1), 49% (95% CI: 28–63) against influenza A(H3N2) and 75% (95% CI: 58–85) against influenza B.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference12 articles.

1. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023 southern hemisphere influenza season. Geneva: WHO; 2022. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-southern-hemisphere-influenza-season

2. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO; 2022. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season

3. Covid-19 Vaccine effectiveness against the Omicron (B.1.1.529) variant.;Andrews;N Engl J Med,2022

4. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.;Vasileiou;Lancet,2021

5. Estimated effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes.;Buchan;JAMA Netw Open,2022

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures;Vaccine;2024-10

2. Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study;Human Vaccines & Immunotherapeutics;2024-08-29

3. Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023–2024 Season;Open Forum Infectious Diseases;2024-08-21

4. Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom;Influenza and Other Respiratory Viruses;2024-05

5. Influenza vaccine effectiveness against hospital-attended influenza infection in 2023/24 season in Hangzhou, China;2024-05-01